
Celcuity Inc. (NASDAQ:CELC) stock surged on Monday after the company reported topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial, which evaluated gedatolisib plus fulvestrant with and without palbociclib versus fulvestrant.
The trial included adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA wild-type, locally advanced or metastatic breast cancer, following progression on, or after, treatment with a CDK4/6 inhibitor and an aromatase inhibitor.